KarinCA's  Instablog

KarinCA
Send Message
Independent writer/trader/investor that tends to write more for informational purposes than to advance a particular position. Please click to follow me if you like my work.  There’s an option to follow me at the top of my articles. Best functionality of site is on desktop. OTHER PLACES TO FOLLOW... More
  • TKMR And It's TKM-Ebola Therapy 2 comments
    Aug 20, 2014 5:09 PM | about stocks: ABUS

    The next meaningful headline may come out of the meeting being held on Sept 4, 2014.

    With Aid Doctors Gone, Ebola Fight Grows Harder
    http://nyti.ms/1liaKI7

    Quote:
    "Dr. Kieny has begun cataloging available doses of experimental drugs and vaccines in preparation for a Sept. 4 meeting on their possible use and testing in the outbreak."

    I'd hate to be short if Tekmira's TKM-ebola ends up on that list of experimental treatments to be tried. And, odds are high it will be tried since the animal studies did well.

    The TKMR pipeline includes several other things of interest. The Ebola scare has brought new eyes to this.

    http://files.shareholder.com/downloads/ABEA-50QJTB/3385729435x0x776430/9ba238a5-3f63-472c-a216-5ceff37b77d0/TKMR_News_2014_8_13_General_Releases.pdf

    Quote:

    "Within our TKM-PLK1 clinical trial targeting GI-NET and ACC patients, we saw an additional RECIST qualifying Partial Response (PR), defined as a greater than 30 percent reduction in target tumor lesions. This patient is continuing on therapy and has achieved a 44 percent reduction in their target tumor mass, located outside of the liver. Furthermore, scans of the target tumor lesions demonstrate signs of necrosis, indicative of anti-tumor activity.

    • We have initiated a Phase I/II clinical study of TKM-PLK1 in patients with Hepatocellular Carcinoma (NYSE:HCC).

    • We intend to file an Investigational New Drug (NYSE:IND) application, or equivalent, in the second half of 2014, in order to advance our TKM-HBV program into a Phase I clinical study, with initial data available in 2015. "

    Long or short, it's a high risk play if you aren't in for a long term investment. Trading is very volatile now.

    Disclosure: The author is long TKMR.

    Stocks: ABUS
Back To KarinCA's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (2)
Track new comments
  • KarinCA
    , contributor
    Comments (571) | Send Message
     
    Author’s reply » Nigeria’s government has requested experimental drug TKM-Ebola from Vancouver-based Tekmira Pharmaceuticals Corp. (NASDAQ:TKMR), Chukwu told reporters in the capital, Abuja.
    http://bloom.bg/1liqICb
    20 Aug 2014, 08:41 PM Reply Like
  • XavierD
    , contributor
    Comments (14) | Send Message
     
    Thanks Karin for the update.
    TKM-HBV is probably the most valuable asset for Tekmira. I agree with you, long term, this is an excellent risk/reward investment.
    20 Aug 2014, 10:07 PM Reply Like
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.